Core Insights - McKesson Corporation has a market capitalization of $97.9 billion and is a leader in healthcare services and information technology, operating through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International [1] Financial Performance - McKesson is expected to announce its fiscal Q2 2026 results on November 5, with analysts forecasting an adjusted EPS of $8.92, representing a 26.2% increase from $7.07 in the same quarter last year [2] - For fiscal 2026, analysts predict an adjusted EPS of $38.12, a 15.3% increase from $33.05 in fiscal 2025 [3] Stock Performance - Over the past 52 weeks, McKesson's stock has increased by 54.9%, outperforming the S&P 500 Index's rise of 15.1% and the Health Care Select Sector SPDR Fund's decline of 3.1% [4] Recent Developments - Despite reporting a better-than-expected Q1 2026 adjusted EPS of $8.26 and revenue of $97.83 billion, McKesson's shares fell by 5.8% the following day due to a 10.7% drop in GAAP EPS to $6.25, attributed to a $189 million bad debt provision related to the Rite Aid bankruptcy [5] Analyst Ratings - The consensus rating for McKesson stock is bullish, with a "Strong Buy" rating from 12 out of 17 analysts, while the average price target is $839.27, indicating a potential upside of 6.3% from current levels [6]

Core Insights - Cardinal Health, Inc. is a healthcare services and products company with a market cap of $36.6 billion, providing a range of services including pharmaceutical distribution and healthcare product manufacturing [1] - The company is expected to announce its fiscal first-quarter earnings for 2026 on October 30, with analysts predicting a profit of $2.21 per share, a 17.6% increase from the previous year [2] - For the full fiscal year, analysts forecast an EPS of $9.45, reflecting a 14.7% increase from $8.24 in fiscal 2025, and an expected rise to $10.58 in fiscal 2027 [3] Stock Performance - Cardinal Health's stock has underperformed compared to the S&P 500 Index, which gained 14.7% over the past 52 weeks, while CAH shares increased by 39% [4] - Following a mixed Q4 earnings report, CAH shares dropped 7.2%, despite an adjusted EPS of $2.08 beating estimates, while revenue of $60.2 billion slightly missed expectations [5] Analyst Ratings - The consensus opinion on CAH stock is bullish, with a "Strong Buy" rating from 11 out of 15 analysts, while four analysts recommend a "Hold" [6] - The average analyst price target for CAH is $179.80, indicating a potential upside of 15.5% from current levels [6]